Abstract:Erik Briffault, 1, 2 Ricardo Reyes, 2, 3 Patricia Garcia-Garcia, 1, 2 Helena Rouco, 1 Luis Diaz-Gomez, 4 Maria Rosa Arnau, 2, 5 Carmen Evora, 1, 3 Patricia Diaz-Rodriguez, 2, 4 Araceli Delgado 1, 2 1 Department of Chemical Engineering and Pharmaceutical Technology, Universidad de La Laguna, La Laguna, 38206, Spain; 2 Institute of Biomedical Technologies (ITB), Universidad de La Laguna, La Laguna, 38320, Spain; 3 Department of Biochemistry, Microbiology, Cell Biology and Genetics, Universidad de La Laguna, La Laguna, 38200, Spain; 4 Department of Pharmacology, Pharmacy and Pharmaceutical Technology, I+D Farma Group (GI-1645), Facultad de Farmacia, Instituto de Materiales (iMATUS) and Health Research Institute of Santiago de Compostela (IDIS), Universidade de Santiago de Compostela, Santiago de Compostela, 15782, Spain; 5 Servicio de Estabulario, Universidad de La Laguna, La Laguna, 38206, Spain Correspondence: Patricia Diaz-Rodriguez; Araceli Delgado, Email ; Introduction: Osteoporosis is a metabolic disorder characterized by the loss of bone mass and density. Nucleic acid-based therapies are among the most innovative approaches for osteoporosis management, although their effective delivery to bone tissue remains a challenge. In this work, SFRP1-silencing GampeR loaded-nanoparticles were prepared and functionalized with specific moieties to improve bone targeting and, consequently, therapeutic efficacy. SFRP1-silencing would promote osteoblastic differentiation by enhancing the WNT/β-catenin pathway and thus diminishing the progression of osteoporosis. Methods: A nucleic acid-based delivery system consisting of lipid-polymer hybrid nanoparticles (LPNPs) loading a GapmeR for SFRP1 silencing was developed and further functionalized with two bone-targeting moieties: a specific aptamer (Apt) for murine mesenchymal stem cells and an antiresorptive drug, namely alendronate (ALD). These systems were tested in vivo in osteoporotic mice at different dosage regimens to analyze dose dependence in bone-forming activity and potential toxicity. The quality of trabecular and cortical bone was assessed by both micro computed tomography (micro-CT) and histological and histomorphometric analyses. Early and late osteogenesis were quantified by immunohistochemistry. Results: Results showed that functionalizing LPNPs loaded with an SFRP1-silencing GapmeR using both Apt and ALD improved bone quality and enhanced osteogenesis following a dose–effect relationship, as revealed by micro-CT, histological and immunohistochemical analyses. In contrast, non-functionalized LPNPs did not produce these effects. Conclusion: These findings highlight the relevance of proper targeting and dosage in nucleic acid-based therapeutics, proving to be crucial for exerting their therapeutic effect: a deficient targeting strategy and/or dosage may result in the therapeutic failure of an adequate gene therapy agent. Keywords: osteoporosis, bone targeting, nanoparticle dose-effect, gene therapy, aptamer, alendronate, micro-CT Graphical Despite the vast efforts and resources focused on the stimulation of bone formation in systemic bone-related pathologies such as osteoporosis, the improvement of the osseous tissue quality remains challenging. 1 The associated diminished bone strength and stiffness increases the risk of bone fractures after low-energy injuries leading to fragility fractures. These fractures represent an economic burden and are only going to become an ever-increasing problem with the aging of the population. Just in 2010 fragility fracture treatment represented 22.42 billion euros in Europe. 2 Moreover, the established pro-degradative environment that imbalances the normal tissue homeostasis impairs bone formation, thus increasing the risk of non-union bone fractures and implant failure. 3–8 Different strategies have been screened in order to counterbalance this situation, including antiresorptive drugs such as bisphosphonates and RANKL inhibitors or anabolic molecules such as teriparatide, abaloparatide and romosozumab. 9 However, significant drawbacks such as osteonecrosis of the jaw and atypical femoral fractures, frequently described in patients with high-dose or long-term treatments, have limited the use of these therapeutic molecules. 10 Improvements in the nucleic acid-based therapeutic stability and the high throughput discovery of genetic targets have exponentially increased the potential of oligonucleotide therapies to correct or modify cell function. 11 Gene th -Abstract Truncated-

Leveraging selective knockdown of Sost gene by polyethyleneimine-siRNA-chitosan reduced gold nanoparticles to promote osteogenesis in MC3T3-E1 & MEF cells

Knockdown of STAT3 Expression in SKOV3 Cells by Biodegradable Sirna–plga/cso Conjugate Micelles

Osteoporosis Remission and New Bone Formation with Mesoporous Silica Nanoparticles

Rational polyelectrolyte nanoparticles endow preosteoclast-targeted siRNA transfection for anabolic therapy of osteoporosis

Reversing the Imbalance in Bone Homeostasis Via Sustained Release of SIRT-1 Agonist to Promote Bone Healing under Osteoporotic Condition

A Delivery System Targeting Bone Formation Surfaces to Facilitate RNAi-based Anabolic Therapy

Incorporation of Osteogenic and Angiogenic Small Interfering RNAs into Chitosan Sponge for Bone Tissue Engineering.

Nanoparticles functionalized with stem cell secretome and CXCR4-overexpressing endothelial membrane for targeted osteoporosis therapy

A bone-targeted engineered exosome platform delivering siRNA to treat osteoporosis

Enhancing Osteoporosis Treatment through Targeted Nanoparticle Delivery of Risedronate: In Vivo Evaluation and Bioavailability Enhancement

Bone-targeted ultrasound-responsive nanobubbles for siRNA delivery to treat osteoporosis in mice

Lipid nanoparticle-mediated silencing of osteogenic suppressor GNAS leads to osteogenic differentiation of mesenchymal stem cells in vivo

Aptamer-functionalized Lipid Nanoparticles Targeting Osteoblasts As a Novel RNA Interference–based Bone Anabolic Strategy

miR4352b a cross-species modulator of SOSTDC1, targets dual pathway to regulate bone health and fracture healing

Ultrasound-Responsive Nanobubbles for Combined siRNA-Cerium Oxide Nanoparticle Delivery to Bone Cells

Delivery of miRNAs Using Porous Silicon Nanoparticles Incorporated into 3D Hydrogels Enhances MSC Osteogenesis by Modulation of Fatty Acid Signalling and Silicon Degradation

Targeting ROS-induced osteoblast senescence and RANKL production by Prussian blue nanozyme based gene editing platform to reverse osteoporosis

Osteoclast-targeted delivery of anti-miRNA oligonucleotides by red blood cell extracellular vesicles

Aptamer-immobilized bone-targeting nanoparticles in situ reduce sclerostin for osteoporosis treatment

SFRP1-Silencing GapmeR-Loaded Lipid-Polymer Hybrid Nanoparticles for Bone Regeneration in Osteoporosis: Effect of Dosing and Targeting Strategy

Sclerostin Transduced Bone Marrow Mesenchymal Stem Cells Promote Fracture Healing in Rats Through the Wnt/β-Catenin Signal Pathway